Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Carfilzomib Induction with Lenalidomide and Clarithromycin Consolidation and Lenalidomide Maintenance (CarBiRD) for Multiple Myeloma (MM)

Peter A. Forsberg, MD, Adriana C Rossi, MD, MSc, Roger N Pearse, MD PhD, Arthur Perry, PA, Karen Pekle, NP, David Jayabalan, BSMS, MSc, Scott Ely, MD MPH, Morton Coleman, MD, John N. Allan, MD, Ruben Niesvizky, MD, Tomer Mark, MD MSc

Blood (2016) 128 (22): 4518.

https://doi.org/10.1182/blood.V128.22.4518.4518

Published: 2016

Journal Articles

Sequencing of Proteasome Inhibitors in Patients with Multiple Myeloma

Benjamin Diamond, MD, Adriana C Rossi, MD, MSc, Roger N Pearse, MD PhD, David Jayabalan, BSMS, MSc, Arthur Perry, PA, Karen Pekle, NP, Tomer Mark, MD MSc, Ruben Niesvizky, MD

Blood (2016) 128 (22): 4522.

https://doi.org/10.1182/blood.V128.22.4522.4522

Published: 2016

Journal Articles

Rising Plasma Cell Proliferation By Ki67/CD138 Ratio at Relapse Is a Marker of High Risk Disease in Multiple Myeloma

Peter A. Forsberg, MD, Tomer M Mark, MD MSc, Sujitha Yadlapati, MBBS, Adriana C Rossi, MD MHS, Roger N Pearse, MD PhD, Karen Pekle, NP, Arthur Perry, PA, Morton Coleman, MD, David Jayabalan, BSMS, MSc, Ruben Niesvizky, MD, Scott Ely, MD MPH

Blood (2015) 126 (23): 2991.

https://doi.org/10.1182/blood.V126.23.2991.2991

Published: 2015

Journal Articles

High-Dose Carfilzomib and Dexamethasone As First-Line Treatment in Symptomatic Multiple Myeloma

Tomer M Mark, MD MSc, Sujitha Yadlapati, MBBS, Lyubov Neglyad, Jennifer Bourke, RN, David Jayabalan, BSMS, MSc, Adriana C Rossi, MD, Roger N Pearse, MD PhD, Arthur Perry, PA, Karen Pekle, NP, Kathleen Pogonowski, RN, Linda Tegnestam, RN, Xiangao Huang, PhD, Maurizio Di Liberto, PhD, Scott Ely, MD MPH, Morton Coleman, MD, Selina Chen-Kiang, PhD, Ruben Niesvizky, MD

Blood (2015) 126 (23): 4258.

https://doi.org/10.1182/blood.V126.23.4258.4258

Published: 2015

Journal Articles

Clapd (Clarithromycin, Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma Overcomes Negative Prognostic Impact of Adverse Cytogenetics and Prior Resistance to Lenalidomide and Bortezomib

Tomer M Mark, MD MSc, Angelique Boyer, Sujitha Yadlapati, MBBS, Adriana C Rossi, MD, Roger N Pearse, MD PhD, Karen Pekle, NP, Arthur Perry, PA, Kathleen Pogonowski, RN, Ekta Aneja, MD, Linda Tegnestam, RN, David Jayabalan, BSMS, MSc, Scott Ely, MD MPH, Morton Coleman, MD, Xiangao Huang, PhD, Maurizio Di Liberto, PhD, Selina Chen-Kiang, PhD, Ruben Niesvizky, MD

Blood (2015) 126 (23): 4232.

https://doi.org/10.1182/blood.V126.23.4232.4232

Published: 2015

Journal Articles

The Clinical Utility of Bone Resorption and Bone Formation Markers in Multiple Myeloma

Shahdabul Faraz, B.S., Roger N Pearse, MD PhD, Sujitha Yadlapati, MBBS, David Jayabalan, BSMS, MSc, Adriana C Rossi, MD MHS, Tomer M Mark, MD MSc, Ruben Niesvizky, MD, Joseph Lane, MD

Blood (2015) 126 (23): 5373.

https://doi.org/10.1182/blood.V126.23.5373.5373

Published: 2015

Journal Articles

Inhibition of CDK4/CDK6 Sensitizes Myeloma to IMiD By Reducing the MEIS2 to Cereblon Ratio That Accelerates IKZF1 and IKZF3 Degradation

Xiangao Huang, PhD, David Jayabalan, BSMS, MSc, Maurizio Di Liberto, PhD, Zhengming Chen, PhD, Anna C Schinzel, PhD, Scott Ely, MD MPH, Adriana C Rossi, MD MHS, Roger N Pearse, MD PhD, Ekta Aneja, MBBS, Morton Coleman, MD, Joseph M Lane, MD, William C. Hahn, MD PhD, Tomer M Mark, MD MSc, Ruben Niesvizky, MD, Selina Chen-Kiang, PhD

Blood (2015) 126 (23): 500.

https://doi.org/10.1182/blood.V126.23.500.500

Published: 2015

Journal Articles

The Ki67/CD138 Ratio Independently Predicts Overall Survival in the Upfront Treatment of Newly Diagnosed Multiple Myeloma

Tomer M Mark, MD MSc, Peter Forsberg, MD, Ihsane Ouansafi, MD, Adriana C Rossi, MD, Roger N Pearse, MD PhD, Karen Pekle, NP, Arthur Perry, PA, Morton Coleman, MD, David Jayabalan, BSMS, MSc, Ruben Niesvizky, MD, Scott A Ely, MD MPH

Blood (2014) 124 (21): 2016.

https://doi.org/10.1182/blood.V124.21.2016.2016

Published: 2014

Journal Articles

Haplo-Cord UCB SCT with Low Cell Dose, Well Matched UCB Units. a Prospective Multicenter Study

Koen van Besien, MD PhD, Hongtao Liu, MD PhD, Usama Gergis, MD, Melissa M. Cushing, MD, Stephanie Tsai, MD, Sebastian Mayer, MD, Amittha Wickrema, PhD, Wendy Stock, MD, Richard A. Larson, Tsiporah B. Shore, MD, Olatoyosi Odenike, MD, Roger N Pearse, MD PhD, Lucy A Godley, MD PhD, Tomer M Mark, MD MSc, Justin Kline, MD, John M Cunningham, MD, James LaBelle, MD PhD, Michael R Bishop, MD, Andrew S. Artz, MD MS

Blood (2014) 124 (21): 1093.

https://doi.org/10.1182/blood.V124.21.1093.1093

Published: 2014

Journal Articles

PET/CT Evaluation As a Prognostic Indicator In Relapsed Or Refractory Multiple Myeloma

Adriana C Rossi, MD, Tomer M Mark, MD, MSc, Kevin Wood, MD, Roger N Pearse, MD, PhD, Faiza Zafar, PA, Karen Pekle, NP, Stanley Goldsmith, MD, Ruben Niesvizky, MD

Blood (2013) 122 (21): 1878.

https://doi.org/10.1182/blood.V122.21.1878.1878

Published: 2013

Journal Articles

Sequence Impact Of Pomalidomide and Carfilzomib On Treatment Response In Relapsed Multiple Myeloma

Tomer M Mark, MD, MSc, John N. Allan, MD, Angelique Boyer, Adriana C Rossi, MD, Roger N Pearse, MD, PhD, Faiza Zafar, PA, Karen Pekle, NP, Linda Tegnestam, RN, David Jayabalan, B.S.M.S, Morton Coleman, MD, Ruben Niesvizky, MD

Blood (2013) 122 (21): 1954.

https://doi.org/10.1182/blood.V122.21.1954.1954

Published: 2013

Journal Articles

Clapd (Clarithromycin, Pomalidomide, Dexamethasone) Therapy In Relapsed Or Refractory Multiple Myeloma

Tomer M Mark, MD, MSc, Angelique Boyer, Adriana C Rossi, MD, Dennis Kwon, Roger N Pearse, MD, PhD, Faiza Zafar, PA, Karen Pekle, NP, Linda Tegnestam, RN, David Jayabalan, B.S.M.S, Scott A Ely, MD, MPH, Morton Coleman, MD, Selina Chen-Kiang, PhD, Ruben Niesvizky, MD

Blood (2013) 122 (21): 1955.

https://doi.org/10.1182/blood.V122.21.1955.1955

Published: 2013

Journal Articles

Car-Bird [Carfilzomib, Clarithromycin(Biaxin (R) ), Lenalidomide/(Revlimid (R) ), Dexamethasone) For Newly-Diagnosed Multiple Myeloma

Tomer M Mark, MD, MSc, John N. Allan, MD, Geoffrey Marano, Adriana C Rossi, MD, Roger N Pearse, MD, PhD, Faiza Zafar, PA, Linda Tegnestam, RN, Karen Pekle, NP, David Jayabalan, B.S.M.S, Morton Coleman, MD, Scott A Ely, MD, MPH, Ruben Niesvizky, MD

Blood (2013) 122 (21): 3216.

https://doi.org/10.1182/blood.V122.21.3216.3216

Published: 2013

Journal Articles

ClaPD (Clarithromycin, Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma

Tomer M Mark, MD, MSc, Angelique Boyer, Adriana C Rossi, MD, Manan Shah, Roger N Pearse, MD, PhD, Faiza Zafar, PA, Karen Pekle, NP, Linda Tegnestam, RN, Erlinda A Sacris, RN, June Greenberg, RN, Stephanie Speaker, David Jayabalan, B.S.M.S, Scott A Ely, MD, MPH, Morton Coleman, MD, Selina Chen-Kiang, PhD, Ruben Niesvizky, MD

Blood (2012) 120 (21): 77.

https://doi.org/10.1182/blood.V120.21.77.77

Published: 2012

Journal Articles

ClaPD (Clarithromycin/[Biaxin®], Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma

Tomer M Mark, MD, MSc, Melissa Rodriguez, Manan Shah, Ryann Quinn, Jessica Campbell, Ramsey Abdullah, Roger N Pearse, MD, PhD, Faiza Zafar, PA, Karen Pekle, NP, Patrice Mignott, RN, David Jayabalan, B.S.M.S, Scott A Ely, MD, MPH, Morton Coleman, MD, Selina Chen-Kiang, PhD, Ruben Niesvizky, MD

Blood (2011) 118 (21): 635.

https://doi.org/10.1182/blood.V118.21.635.635

Published: 2011

Journal Articles

A Novel Sequential Treatment Utilizing CPX-351 As Salvage Chemotherapy Followed by a Reduced Intensity Conditioning Allogeneic Stem-Cell Transplantation for Patients with Refractory Leukemia

Usama Gergis, MD, Gail J. Roboz, MD, Ellen Ritchie, MD, Joseph M. Scandura, MD, PhD, Karen-Sue B. Carlson, MD, PhD, Tsiporah B. Shore, MD, Sebastian Mayer, MD, Tomer M Mark, MD, MSc, Roger N Pearse, MD, PhD, June Greenberg, Tania J Curcio, R.N, Cindy Ippoliti, PharmD, Marshall McKenna, Eric J Feldman, MD

Blood (2011) 118 (21): 3030.

https://doi.org/10.1182/blood.V118.21.3030.3030

Published: 2011

Journal Articles

A Phase 1 Study of Bendamustine and Melphalan Conditioning for Autologous Stem Cell Transplant in Multiple Myeloma

Tomer M Mark, MD, MSc, Whitney Reid, Ruben Niesvizky, MD, Usama Gergis, MD, Roger N Pearse, MD, PhD, Sebastian Mayer, MD, Morton Coleman, MD, Eric J Feldman, MD, Tsiporah B. Shore, MD

Blood (2011) 118 (21): 2042.

https://doi.org/10.1182/blood.V118.21.2042.2042

Published: 2011

Journal Articles

T-Bird (thalidomide, clarithromycin/[Biaxin®], lenalidomide/[Revlimid ® ], Dexamethasone) Therapy in Newly Diagnosed Symptomatic Multiple Myeloma

Tomer M Mark, MD, MSc, Manan Shah, Melissa Rodriguez, Ryann Quinn, Roger N Pearse, MD, PhD, Faiza Zafar, PA, Karen Pekle, NP, Patrice Mignott, RN, David Jayabalan, B.S.M.S, Scott A Ely, MD, MPH, Morton Coleman, MD, Selina Chen-Kiang, PhD, Ruben Niesvizky, MD

Blood (2011) 118 (21): 2937.

https://doi.org/10.1182/blood.V118.21.2937.2937

Published: 2011

Journal Articles

MAGE-A Inhibits Apoptosis In Proliferating Multiple Myeloma Cells

Tricia Nardiello, BA, Achim A Jungbluth, MD, Anna Mei, BA, Maurizio DiLiberto, PhD, Xiangao Huang, PhD, Scott A Ely, MD, MPH, Ruben Niesvizky, MD, Morton Coleman, MD, Roger N Pearse, MD, PhD, David Jayabalan, B.S.M.S, Lloyd J Old, MD, Selina Chen-Kiang, PhD, Hearn J. Cho, MD, PhD

Blood (2010) 116 (21): 785.

https://doi.org/10.1182/blood.V116.21.785.785

Published: 2010

Journal Articles

Autologous Stem Cell Transplantation Is Feasible and of Potential Benefit In Very Elderly Patients with Lymphoma and Limited Comorbidities

Rebecca Elstrom, MD, Peter Martin, FRCPC, MD, MS, Tsiporah B. Shore, MD, Richard R. Furman, MD, Jia Ruan, MD, PhD, Tomer M Mark, MD, MSc, Roger N Pearse, MD, PhD, Morton Coleman, MD, John P. Leonard, MD, Usama Gergis, MD

Blood (2010) 116 (21): 3561.

https://doi.org/10.1182/blood.V116.21.3561.3561

Published: 2010

NARROW

Carfilzomib Induction with Lenalidomide and Clarithromycin Consolidation and Lenalidomide Maintenance (CarBiRD) for Multiple Myeloma (MM)

Sequencing of Proteasome Inhibitors in Patients with Multiple Myeloma

Rising Plasma Cell Proliferation By Ki67/CD138 Ratio at Relapse Is a Marker of High Risk Disease in Multiple Myeloma

High-Dose Carfilzomib and Dexamethasone As First-Line Treatment in Symptomatic Multiple Myeloma

Clapd (Clarithromycin, Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma Overcomes Negative Prognostic Impact of Adverse Cytogenetics and Prior Resistance to Lenalidomide and Bortezomib

The Clinical Utility of Bone Resorption and Bone Formation Markers in Multiple Myeloma

Inhibition of CDK4/CDK6 Sensitizes Myeloma to IMiD By Reducing the MEIS2 to Cereblon Ratio That Accelerates IKZF1 and IKZF3 Degradation

The Ki67/CD138 Ratio Independently Predicts Overall Survival in the Upfront Treatment of Newly Diagnosed Multiple Myeloma

Haplo-Cord UCB SCT with Low Cell Dose, Well Matched UCB Units. a Prospective Multicenter Study

PET/CT Evaluation As a Prognostic Indicator In Relapsed Or Refractory Multiple Myeloma

Sequence Impact Of Pomalidomide and Carfilzomib On Treatment Response In Relapsed Multiple Myeloma

Clapd (Clarithromycin, Pomalidomide, Dexamethasone) Therapy In Relapsed Or Refractory Multiple Myeloma

Car-Bird [Carfilzomib, Clarithromycin(Biaxin (R) ), Lenalidomide/(Revlimid (R) ), Dexamethasone) For Newly-Diagnosed Multiple Myeloma

ClaPD (Clarithromycin, Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma

ClaPD (Clarithromycin/[Biaxin®], Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma

A Novel Sequential Treatment Utilizing CPX-351 As Salvage Chemotherapy Followed by a Reduced Intensity Conditioning Allogeneic Stem-Cell Transplantation for Patients with Refractory Leukemia

A Phase 1 Study of Bendamustine and Melphalan Conditioning for Autologous Stem Cell Transplant in Multiple Myeloma

T-Bird (thalidomide, clarithromycin/[Biaxin®], lenalidomide/[Revlimid ® ], Dexamethasone) Therapy in Newly Diagnosed Symptomatic Multiple Myeloma

MAGE-A Inhibits Apoptosis In Proliferating Multiple Myeloma Cells

Autologous Stem Cell Transplantation Is Feasible and of Potential Benefit In Very Elderly Patients with Lymphoma and Limited Comorbidities

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only